. Overall, am-P p .0009) picillin/sulbactam eradicated pathogens from the major abscesses in 100% of patients, whereas the eradication rate with cefoxitin was 97.9%. The 2 drugs were well tolerated. Ampicillin/ sulbactam and cefoxitin were equally effective for the empirical treatment of cutaneous or other soft-tissue infections in injection drug abusers and patients who did not inject drugs.
regimen. Drug-abusing patients may have an increased likelihood of other diseases, such as HIV infection and chronic liver disease [3] , and infection sites may be compromised by the vasoconstrictive effects of drugs such as cocaine, which decrease oxygen tension in surrounding tissues and inhibit the bactericidal capacity of polymorphonuclear leukocytes [3] .
Treatment of cutaneous abscesses in both parenteral drug users and patients who did not inject drugs (nonusers) is further complicated by a relatively wide range of causative pathogens [1, [13] [14] [15] [16] . Whereas routine skin infections caused by Staphylococcus aureus and/or Streptococcus pyogenes may respond to first-generation cephalosporins, antistaphylococcal penicillins, or vancomycin, cutaneous abscesses may require broader-spectrum antimicrobial therapy. In one evaluation [13] of the microbiology of 676 skin or soft-tissue infections in patients who were not specifically identified as drug users, multiple pathogens occurred in 38%. The most common aerobes were S. aureus and alpha-hemolytic streptococci, and the most common anaerobe was Bacteroides fragilis. In another report [1] , two-thirds of infections in outpatients contained multiple pathogens, most commonly S. aureus and Bacteroides species. Cutaneous and other soft-tissue infections in parenteral drug users are also frequently polymicrobial [14, 15] .
Given the mixed bacterial etiology of such infections in both drug users and nonusers and given the need to initiate treatment before the results of antimicrobial susceptibility tests are known, empirical therapy with broad-spectrum antimicrobials may be appropriate [17] . Two possible options are use of a second-generation cephalosporin with anaerobic activity or use of a combination of a b-lactam antibiotic with a b-lactamase inhibitor. This study compared the safety and efficacy of cefoxitin and ampicillin/sulbactam in the treatment of cutaneous and other soft-tissue infections in patients with or without histories of injection drug abuse.
Methods
Patients. Patients were enrolled in 1 of 2 concurrent studies at Olive View-University of Californina Los Angeles Medical Center (Sylmar, CA) from May 1992 through September 1994. One study included patients with no histories of injection drug abuse, and the other enrolled only patients with such histories.
Eligible patients in the first trial were hospitalized, were at least 18 years of age, and had a clinically established diagnosis of skin or other soft-tissue abscesses, which were defined as postoperative skin, suture, or soft-tissue wound abscesses (diagnosed up to 10 days post surgery), perirectal/perianal abscesses, infected breast cysts that had become abscessed, or any other skin or subcutaneous tissue abscess not clearly falling within one of these categories that occurred in a nonuser.
Patients in the second trial were also hospitalized and were at least 18 years of age, but they were required to have a clinically established diagnosis of a skin or other soft-tissue abscess thought to be related to parenteral drug abuse.
Diagnostic criteria included the presence of a cutaneous or other soft-tissue abscess, which either required incision and drainage or spontaneously drained, with purulent material and at least 3 of the following findings: temperature у38ЊC, a peripheral WBC count 110,000/mm 3 , and/or 15% immature neutrophils, local erythema or swelling, and pain/tenderness.
Bacteriologic criteria specified the performance of at least 1 aerobic and 1 anaerobic culture of abscess material р48 h prior to the start of therapy, predominance of polymorphonuclear cells and bacterial organisms in material from the abscess, and performance of 2 sets of cultures (aerobic and anaerobic) of blood from separate venipuncture sites р48 h prior to the start of therapy.
The following exclusion criteria were applied: known or suspected hypersensitivity to penicillins, study drugs, or any b-lactam antibiotics; infection with an organism known to be resistant to either study regimen; terminal illness, likelihood of death within 48 h, or any severe underlying disease that might interfere with evaluation of the therapeutic response; expectation of hospital discharge in !4 days; necrotizing fasciitis; likely need for amputation of the infected area; treatment with an investigational drug within 30 days; use of another antibacterial agent within 48 h without evidence of treatment failure; immunologic or hematologic disorders or malignancies that the investigator believed would either interfere with the normal clinical response to antimicrobial therapy or increase the risk of an adverse experience; and pregnancy or nursing status.
Bacteriologic studies. Detailed bacteriologic analysis was completed for the major abscess, which was defined as the largest abscess in a given patient. Pretreatment specimens for culture were obtained within 48 h prior to initiation of therapy, either by syringe and needle aspiration or by swabbing of the draining material. Each probable pathogen was identified, if possible, to the species level, and the amount of growth was semiquantitated. Anaerobic and aerobic cultures were repeated on day 3 or 4 of therapy if satisfactory material was available and on day 8 or 9 if signs of infection persisted.
Investigators rated the pathogenicity of each organism isolated from the major abscess as follows: a major pathogen had a major role in the infection and necessitated specific antibacterial therapy, a minor pathogen had an uncertain role and may not have necessitated specific antibacterial therapy, and a nonpathogen contaminant was probably not present at the infection site and was isolated as a result of contamination. The classification of pathogens was based on the clinical importance of the species isolated, the quantity of bacteria, and the number of associated WBCs. Only major pathogens are reported. All aerobic pathogens were tested for susceptibility to study drugs by use of the Kirby-Bauer disk method, and all anaerobic pathogens were tested by the agar-dilution method approved by the National Committee for Clinical Laboratory Standards [18, 19] . All pathogens were tested for b-lactamase production with use of the nitrocefin test (or equivalent). Antimicrobial therapy. Patients were randomized to receive thirdparty-blinded treatment with either ampicillin/sulbactam (2 g/1 g) or cefoxitin (2 g), each administered iv every 6 h. The minimum duration of treatment was 3 days (12 doses) for each drug; the maximum treatment period was based on the investigators' judgment and the patients' responses. Patients were not permitted to receive additional oral or parenteral antibiotic agents during the study, but they could be treated with any other necessary medication.
Evaluation. Each patient was evaluated clinically and bacteriologically up to 48 h prior to study enrollment. Evaluations of clinical and bacteriologic outcomes were made without knowledge of the patients' treatment group.
Maximum daily temperature, quantitative and qualitative description of drainage, area and severity of induration and erythema, presence or absence of rigors, and pain, all since previous examination, were recorded. Closed abscesses were incised and drained, and wounds associated with spontaneously draining abscesses were surgically extended and drained. Any other operative procedures, including débridement, were recorded.
Detailed clinical evaluations were done at enrollment, and clinical response was assessed daily during the first week of treatment while the patient was hospitalized, on the last day of therapy, and (whenever possible) within 3 days after therapy was completed. Additional follow-up evaluations were also conducted by clinic visit or telephone contact within the first 2 weeks after completion of therapy. All clinical assessments were made by one study coordinator and were verified by the principal investigator (D.A.T.).
Clinical responses were defined as follows. Cure was defined as complete clinical recovery that was evident at the end-of-therapy and post-therapy evaluations following completion of a full course of therapy. Improvement was defined as the improvement or return to normal of at least 3 of the following-quality and quantity of drainage, erythema, swelling, temperature, and peripheral WBC count-in comparison with the pre-enrollment evaluation and without any clinically significant deterioration during therapy. Relapse was defined as initial improvement of at least 3 efficacy measures, followed by clinically significant worsening of at least 1 efficacy measure during therapy. Failure was defined as therapeutic failure requiring a change in or addition of antibacterial therapy.
Determination of bacteriologic outcomes and classification of pathogens as major or minor were accomplished by the principal investigators (D.A.T. and S.M.F.). The following criteria were used to define bacteriologic response to treatment. Eradication was the disappearance of culturable material or the elimination of pathogen(s) (for those with у2ϩ growth in a pretreatment specimen) at the end of therapy. Eradication/superinfection was defined by the disappearance of culturable material and/or the elimination of principal (numerically dominant) organism(s) from the target lesion and the emergence of a different pathogenic organism(s), either during or at the end of therapy, with continued appearance or reappearance of signs of infection.
Partial eradication was the disappearance of some pathogens isolated initially (mixed infections). Partial eradication could also be determined by reduction in counts of the majority of pretherapy major pathogens if quantitative or semiquantitative data were available. Persistence was defined by the persistence of all major pathogens at the end of therapy. The outcome was considered to be indeterminable if results were unevaluable or if the response did not fall into the categories described.
Adverse events. Investigators designated all adverse events as drug-related or not and recorded their severity and duration, the action taken, and outcome. Follow-up was maintained until all adverse events resolved.
Data Analysis. Baseline demographic data for the 2 treatment groups were compared by means of Fisher exact tests, the MantelHaenzel x 2 statistic, and Wilcoxon rank-sum tests. For clinical outcomes, the relapse and failure categories were combined. The resulting distributions of clinical outcomes (cured vs. failed) were compared for the 2 treatments by means of Fisher exact test. For bacteriologic responses, the distributions (eradication ϩ eradication/superinfection vs. partial eradication ϩ persistence) were compared by means of the Mantel-Haenzel x 2 statistic. Times from initiation of therapy to resolution of all symptoms and number of hospital days were compared by means of the Wilcoxon rank-sum test. Analyses were performed for all patients and separately for those with or without histories of injection drug abuse. A value of P ! .05 was considered to be statistically significant in all tests. 
Results

Demographic characteristics.
A total of 114 patients were enrolled: 58 were randomized to receive ampicillin/sulbactam and 56 to receive cefoxitin. Eighteen patients (9 ampicillin/sulbactam recipients and 9 cefoxitin recipients) were excluded from the efficacy analysis because of protocol violations. Reasons for exclusion among patients randomized to the ampicillin/sulbactam group were noncompliance (2 patients), patient's request to stop treatment (2), patient left hospital (2), concomitant illness (1), use of prohibited medication (1), and no pathogen isolated (1). Reasons for exclusion among patients randomized to the cefoxitin group were patient's request to stop treatment (3), patient left hospital (1), concomitant illness (2), premature withdrawal (2), and use of prohibited medication (1). Patients were not excluded if bacteriologic analysis identified a pathogen resistant to the assigned antimicrobial therapy. Table 1 summarizes the demographic characteristics of the 49 efficacy-evaluable patients who received ampicillin/sulbactam and the 47 who were treated with cefoxitin. No significant differences were noted between the 2 groups. Incision and drainage were performed in 38 nonusers (18 treated with ampicillin/ sulbactam and 20 treated with cefoxitin) and 34 drug users (19 treated with ampicillin/sulbactam and 15 treated with cefoxitin); other patients had surgical extension of spontaneously draining wounds. Of further note, diabetes was noted in 12 patients (24%) without histories of injection drug abuse, compared with 2 patients (4%) with histories of injection drug abuse. However, the proportions of patients with diabetes in each treatment group were similar.
Clinical response. Clinical responses at the end of therapy were similar in both groups (figure 1). A total of 44 (89.8%) of 49 patients treated with ampicillin/sulbactam and 44 (93.6%) Patients who received ampicillin/sulbactam required a median of 10.5 days (interquartile range, 7-17 days) of treatment for complete resolution of clinical symptoms of infection, and patients treated with cefoxitin required a median of 15.5 days (interquartile range, 7-19 days) (no statistically significant difference between treatments). Times to symptom resolution were generally similar for the patients with and without histories of injection drug abuse. For drug users, median times to complete symptom resolution were 15 days (8-17 days) with ampicillin/sulbactam and 17 days (8-20 days) with cefoxitin. For nonusers, corresponding periods were 8 days (6-17 days) and 9 days (6-18 days). Neither difference was statistically significant. Table 2 summarizes the times to resolution of individual symptoms. Although, for most variables, less time was required with use of ampicillin/sulbactam, none of these differences were statistically significant.
Durations of therapy and hospitalization. The duration of parenteral antimicrobial therapy was equivalent to the number of hospital days for all patients. The average duration of therapy was days with ampicillin/sulbactam ( 5. doses). None of the between-treatment differences were statistically significant. Bacteriologic response. The bacteriology of the major abscesses differed in several ways between the 2 patient groups. Of the isolates obtained from drug users, 39% contained both aerobic and anaerobic pathogens, compared with 27% of isolates from nonusers (table 3) . In addition, anaerobes-either alone or as part of mixed aerobic-anaerobic infections-were encountered more frequently in drug users than in nonusers (44% vs. 35%) (table 3). The initial data from this study (on 160 major pathogens) have been published elsewhere [16] . The final data (on 265 major pathogens) are presented in Resistance analysis. Analysis of 137 major pathogens from patients who received ampicillin/sulbactam showed that 21.9% (30) were resistant to ampicillin, 0.7% (1) were resistant to ampicillin/sulbactam, and 6.6% (9) were resistant to cefoxitin. Of the 112 major pathogens from cefoxitin-treated patients, 41.1% (46) were resistant to ampicillin, 3.6% (4) were resistant to ampicillin/sulbactam, and 7.1% (8) were resistant to cefoxitin (table  5 and figure 3) .
Safety. Both antimicrobial treatments were well tolerated (table 6). The most common complaints were insomnia, drugwithdrawal syndrome, constipation, dyspepsia, anxiety, and nausea, all of which were mild to moderate in severity. With the exception of drug-withdrawal syndrome, adverse events occurred with similar frequency among the patients with and without histories of injection drug abuse.
The only laboratory abnormalities that occurred in 15% of patients were anemia (8.6% of ampicillin/sulbactam-treated patients vs. 7.1% of those given cefoxitin) and hypokalemia (6.9% vs. 1.8%, respectively). Among nonusers, anemia occurred in 3.3% of patients who received ampicillin/sulbactam and in 6.9% of those treated with cefoxitin. The respective percentages for patients with histories of injection drug abuse were 14.3% and 7.4%. All cases of anemia were ascribed to the patients' associated medical conditions and not to study medications or procedures. Among nonusers, hypokalemia occurred in 6.7% of patients treated with ampicillin/sulbactam and in none of those treated with cefoxitin. The respective values for patients with a history of injection drug abuse were 7.1% and 3.7%.
No clinical adverse events or laboratory abnormalities were considered to be treatment related. One patient died of uppergastrointestinal bleeding 3 months after completion of treatment with ampicillin/sulbactam that resulted in abscess healing. This death was judged to be unrelated to the patient's participation in the study.
Discussion
The results of this study demonstrate that both ampicillin/ sulbactam and cefoxitin are safe and effective for the treatment of cutaneous and other soft-tissue abscesses in patients with or without histories of injection drug abuse. Bacteriologic efficacy was demonstrated even though a significant fraction of the isolated pathogens exhibited in vitro resistance to these antimicrobials (6.6% showing resistance to cefoxitin vs. 0.7% showing resistance to ampicillin/sulbactam). However, in considering this result, it is important to remember that patterns of resistance to ampicillin/sulbactam and cefoxitin may have changed since completion of this study in 1994.
In this study, major cutaneous and other soft-tissue abscesses in drug users and nonusers were often polymicrobial; S. aureus and Streptococcus species were the most common aerobic pathogens, and Prevotella species and Peptostreptococcus species were the most common anaerobes. These findings are consistent with those of previous studies [15, 20] in similar patient populations, in which S. aureus was the pathogen most frequently isolated from cutaneous abscesses.
Peptostreptococcus species, Prevotella species, Fusobacterium nucleatum, and Bacteroides species were cultured from the abscesses of patients with and without histories of injection drug abuse. The recovery rate of B. fragilis was low in comparison with that previously reported [13, 21] , but the reason for this is not clear. Oral anaerobes were frequently recovered from drug users. It has been suggested that the presence of oropharyngeal bacteria in the abscesses of parenteral drug users may be caused by the practice of blowing clots from injection paraphernalia or by using saliva to either lubricate the needle or moisten straining cotton [3] .
In this study, ampicillin/sulbactam and cefoxitin were clinically effective in nearly all evaluable patients. This result was not surprising, because the former antibiotic, a combination of a broad-spectrum b-lactam with a b-lactamase inhibitor, and the latter antibiotic, a second-generation cephalosporin, have proven efficacy in the treatment of complicated skin and skinstructure infections [17, [22] [23] [24] [25] . In addition, some severe abscess infections requiring hospitalization may benefit greatly from incision and drainage alone. In the present study, intensive iv therapy succeeded against pathogens with in vitro resistance to these agents.
The importance of administration of a combination of sulbactam and ampicillin is underscored by the high percentage of pathogens from skin infections resistant to ampicillin alone in both this and other studies [26] . The fact that the present in vitro results were not necessarily predictive of in vivo efficacy underscores the difficulty in anticipating antimicrobial efficacy [27, 28] . Other factors, such as diffusion of the antibiotic to the infection site and the effects of drugs on host immune responses, may also be important determinants of in vivo efficacy [29] .
There were no significant differences between treatments with respect to either the times required for resolution of all symptoms or the duration of therapy and hospitalization. Even a small difference in the duration of iv therapy, however, can have significant impact on overall treatment cost [30] . A recent comparison of the costs of ampicillin/sulbactam and imipenem/ cilastatin for the treatment of lower-limb infections in patients with diabetes demonstrated a very large ($3,000 [U.S.]) perpatient savings with use of ampicillin/sulbactam. This savings was due largely to a shorter hospital stay for the patients who received the b-lactam/b-lactamase inhibitor combination [31] . It is important to note that, although ambulatory iv therapy may have reduced the hospital stays for some of the patients in this study, all patients required hospitalization for surgical management of their abscesses.
In summary, the results of this study support the conclusion that ampicillin/sulbactam and cefoxitin are both safe and effective in the treatment of cutaneous or other soft-tissue abscesses.
